A study of aspirin resistance in type 2 diabetes.
Aspirin is currently known to give inadequate protection against coronary artery disease in diabetes compared to person without it. We evaluated 97 consecutive patients with type 2 diabetes for assessing laboratory aspirin resistance and attempted to assess the impact of various clinical and biochemical parameters on it. Thirty-eight patients (39.1%) were found to be less sensitive to the action of aspirin, 7 persons (7.2%) were found to be resistant and 31 persons (31.9%) were aspirin semi-responders. Only total cholesterol, LDL-cholesterol and triglyceride had statistically significant impact on aspirin resistance (p<0.05). Three persons out of 9 with some form of macrovascular disease had aspirin resistance.
Singla
Mani Kant
MK
Department of Endocrinology, IPGME&R and SSKM Hospital, Kolkata.
Lahiri
Prabir
P
Mukhopadhyay
Pradip
P
Pandit
Kaushik
K
Chaudhuri
Utpal
U
Chowdhury
Subhankar
S
D001241:Aspirin / Q000008:administration & dosage*; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D003925:Diabetic Angiopathies / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D004351:Drug Resistance; D006801:Humans; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D010979:Platelet Function Tests; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D008078:Cholesterol, LDL; D010975:Platelet Aggregation Inhibitors; D014280:Triglycerides; D001241:Aspirin